94
Participants
Start Date
December 18, 2018
Primary Completion Date
December 23, 2019
Study Completion Date
December 23, 2019
SPR206
"SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13."
Placebo
0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Scientia Clinical Research Ltd., Randwick
Lead Sponsor
Collaborators (1)
Clinical Network Services (CNS) Pty Ltd
INDUSTRY
Spero Therapeutics
INDUSTRY